Analysts predict that Soleno Therapeutics Inc (NASDAQ:SLNO) will announce earnings of ($0.14) per share for the current quarter, according to Zacks. Zero analysts have made estimates for Soleno Therapeutics’ earnings. Soleno Therapeutics posted earnings per share of ($0.12) in the same quarter last year, which indicates a negative year-over-year growth rate of 16.7%. The business is scheduled to announce its next earnings results on Monday, March 16th.
According to Zacks, analysts expect that Soleno Therapeutics will report full year earnings of ($0.85) per share for the current year. For the next financial year, analysts expect that the business will report earnings of ($0.84) per share. Zacks’ EPS calculations are an average based on a survey of research analysts that follow Soleno Therapeutics.
Several analysts have issued reports on the company. ValuEngine raised Soleno Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, October 15th. Zacks Investment Research cut Soleno Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday, November 14th.
Shares of NASDAQ:SLNO traded down $0.04 during midday trading on Friday, hitting $1.54. The company had a trading volume of 2,971 shares, compared to its average volume of 58,230. Soleno Therapeutics has a 12-month low of $1.11 and a 12-month high of $5.07. The company has a fifty day moving average of $1.52 and a two-hundred day moving average of $2.05. The company has a market cap of $71.65 million, a price-to-earnings ratio of -2.37 and a beta of 2.33.
In other news, major shareholder Ventures Fund V. L.P. Vivo sold 334,417 shares of the business’s stock in a transaction dated Monday, November 4th. The stock was sold at an average price of $1.50, for a total value of $501,625.50. Also, Director Andrew Sinclair acquired 2,300,000 shares of the stock in a transaction dated Friday, October 25th. The stock was acquired at an average price of $1.53 per share, for a total transaction of $3,519,000.00. Insiders have sold 525,927 shares of company stock worth $800,327 in the last ninety days. Insiders own 26.56% of the company’s stock.
Several hedge funds and other institutional investors have recently added to or reduced their stakes in SLNO. BlackRock Inc. boosted its stake in Soleno Therapeutics by 86.0% in the 2nd quarter. BlackRock Inc. now owns 72,061 shares of the company’s stock worth $202,000 after purchasing an additional 33,319 shares during the period. Vanguard Group Inc. boosted its position in shares of Soleno Therapeutics by 14.1% during the second quarter. Vanguard Group Inc. now owns 243,879 shares of the company’s stock worth $683,000 after acquiring an additional 30,092 shares during the last quarter. Trellus Management Company LLC boosted its position in shares of Soleno Therapeutics by 10.9% during the third quarter. Trellus Management Company LLC now owns 297,132 shares of the company’s stock worth $446,000 after acquiring an additional 29,132 shares during the last quarter. Bank of New York Mellon Corp purchased a new position in Soleno Therapeutics during the second quarter valued at $49,000. Finally, Lindbrook Capital LLC purchased a new position in Soleno Therapeutics during the second quarter valued at $30,000. 32.41% of the stock is owned by hedge funds and other institutional investors.
About Soleno Therapeutics
Soleno Therapeutics, Inc focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is diazoxide choline controlled-release, a tablet that is in Phase III clinical trial for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc and changed its name to Soleno Therapeutics, Inc in May 2017.
Read More: What is the NASDAQ Stock Market?
Get a free copy of the Zacks research report on Soleno Therapeutics (SLNO)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Soleno Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Soleno Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.